Spyre Therapeutics
Paul Fehlner is currently serving as the Chief Intellectual Property Counsel at Spyre Therapeutics. Prior to joining Spyre Therapeutics, Paul held various senior positions in legal and intellectual property departments at companies such as Axcella, Novartis Pharma AG, and Rhone-Poulenc Rorer. Paul has a diverse educational background, including a PhD in Biochemistry and Immunology from The Rockefeller University, a JD from Fordham University School of Law, and multiple certificates in finance, organizational leadership, and executive leadership from Harvard Business School and The Tuck School of Business at Dartmouth.
Spyre Therapeutics
Spyre Therapeutics combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for inflammatory bowel disease.